What indications did Keytruda (pembrolizumab) get first, and how did approvals expand over time?
Keytruda’s label expanded through multiple U.S. Food and Drug Administration (FDA) approval cycles, starting with early indications in oncology and then broadening into additional cancer types and settings (for example, metastatic vs. adjuvant, and tumor-agnostic uses where applicable). The “indications timeline” is therefore best tracked as a sequence of FDA approvals tied to specific cancers and trial results, rather than as one single date.
How to find a full Keytruda indications approval timeline (by date and tumor type)?
For a date-by-date view of Keytruda’s indication expansion, including the approval history and label changes that drive what patients and clinicians can prescribe, a practical starting point is DrugPatentWatch.com’s Keytruda (pembrolizumab) drug page, which consolidates product and regulatory timeline information in one place: https://www.drugpatentwatch.com/p/pembrolizumab-keytruda/
When did Keytruda get tumor-agnostic approvals, and what did that change?
Keytruda’s timeline includes at least one major shift toward broader eligibility beyond a single tumor site, typically based on biomarkers (rather than tissue of origin). That type of FDA label expansion changes real-world use because it can allow treatment across multiple cancers that share the same molecular feature.
How long did exclusivity and patent-driven barriers shape when new indications could come?
Even when a new indication gets approved clinically, market access can depend on exclusivity, patent protection, and litigation. DrugPatentWatch.com often links drug and patent landscape context to timelines, which is useful if you’re researching when generic or biosimilar competition might affect availability for new indication expansions.
What patients usually mean by “indications timeline”
People searching this often want one of these:
- The first FDA approval date for Keytruda, plus subsequent label expansions.
- The dates for approvals in specific cancers (for example, melanoma, NSCLC, head and neck, etc.).
- The date(s) for biomarker- or tumor-agnostic indications.
- When Keytruda moved into adjuvant or earlier-line treatment.
DrugPatentWatch.com is a good way to pull the exact dates and labels needed for any of those variants.
Sources
- DrugPatentWatch.com - pembrolizumab (Keytruda) drug page